Literature DB >> 7108766

Interactions of phenobarbital with propranolol in the dog. 1. Plasma protein binding.

S A Bai, F P Abramson.   

Abstract

A new drug interaction is described in which the plasma binding of propranolol is markedly stimulated by chronic phenobarbital administration in dogs. After 3 weeks of phenobarbital therapy, the percentages of unbound propranolol fell from 15.2 +/- 1.2 (mean +/- S.E.) to 2.4 +/- 0.3 (P less than .001). The time course of the induction and recovery of the binding of propranolol was also investigated. A half-maximal stimulation of binding was seen by day 3 of phenobarbital therapy and a plateau was reached after 2 weeks. After discontinuing phenobarbital, the recovery was delayed with the midpoint of the return to a normal binding value occurring on day 17. A new model of the time course for induction which includes the pharmacokinetics of the inducing agent has been developed. The stimulation of protein production by phenobarbital is assumed to follow Michaelis-Menten kinetics, but with a lag phase for the expression of the induction. Using this model, the Km for phenobarbital-stimulated production of the binding protein was 1200 ng/ml, the turnover T1/2 of the protein was 3.4 days and the T1/2 for the lag phase was also 3.4 days. The increased plasma protein binding was highly correlated (r = 0.97) with the elevated concentration of nonprecipitable glycoproteins. This most likely represents induction of alpha-1 acid glycoprotein which is the principal binding protein of propranolol in man. The plasma binding of propranolol was also stimulated with chronic phenytoin in these dogs and with a single dose of Arochlor 1254 in rats.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7108766

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  12 in total

1.  Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes.

Authors:  A Rostami-Hodjegan; K Wolff; A W Hay; D Raistrick; R Calvert; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  1999-07       Impact factor: 4.335

2.  Enzyme induction and beta-adrenergic receptor blocking drugs.

Authors:  R A Branch; R J Herman
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

3.  Influence of food on the intravenous and oral dose kinetics of propranolol in the dog.

Authors:  S A Bai; U K Walle; T Walle
Journal:  J Pharmacokinet Biopharm       Date:  1985-06

Review 4.  Free drug concentration monitoring in clinical practice. Rationale and current status.

Authors:  C K Svensson; M N Woodruff; J G Baxter; D Lalka
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

5.  Induction of propranolol metabolism by rifampicin.

Authors:  R J Herman; K Nakamura; G R Wilkinson; A J Wood
Journal:  Br J Clin Pharmacol       Date:  1983-11       Impact factor: 4.335

Review 6.  First-pass elimination. Basic concepts and clinical consequences.

Authors:  S M Pond; T N Tozer
Journal:  Clin Pharmacokinet       Date:  1984 Jan-Feb       Impact factor: 6.447

7.  Effects of chlorpromazine on the disposition and beta-adrenergic blocking activity of propranolol in the dog.

Authors:  S A Bai; F P Abramson
Journal:  J Pharmacokinet Biopharm       Date:  1984-06

8.  Disopyramide pharmacokinetics and metabolism: effect of inducers.

Authors:  R P Kapil; J E Axelson; I L Mansfield; D J Edwards; B McErlane; M A Mason; D Lalka; C R Kerr
Journal:  Br J Clin Pharmacol       Date:  1987-12       Impact factor: 4.335

9.  Effect of chronic administration of phenobarbital on the hepatobiliary transport of phenol red: assessment by statistical moment analysis.

Authors:  T Kakutani; K Endo; E Nara; S Nakazora; M Hashida
Journal:  Pharm Res       Date:  1992-07       Impact factor: 4.200

10.  Induction of quinidine metabolism and plasma protein binding by phenobarbital in dogs.

Authors:  A Rakhit; N H Holford; D J Effeney; S Riegelman
Journal:  J Pharmacokinet Biopharm       Date:  1984-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.